Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Selective inhibition of proteinase 3 over human neutrophil elastase by alpha1-protease inhibitor
FY 2016-17
Summary
Neutrophils, though important components of the immune system, can amplify the damage caused in autoimmune diseases by attacking healthy human tissue in the absence of infection. When activated, neutrophils release reactive oxygen species and neutrophil serine proteases (NSP), including proteinase 3 (PR3). Endogenous NSP inhibitors are overwhelmed in inflammatory disease states, leading to damage. Natural NSP inhibitors preferentially inhibit the NSP human neutrophil elastase (HNE), thus, other NSPs like PR3 offer attractive therapeutic targets. A well-known and abundant HNE inhibitor, ?1-protease inhibitor (?1-PI), has been found to preferentially inhibit thrombin and FXIa when the reactive centre loop is mutated. As of yet, there has been no inhibitor, natural or engineered, that successfully, efficiently and preferentially inhibits PR3 over HNE in vivo. The objective of my M.Sc. thesis research will be to select and characterize recombinant ?1-PI variants that react with PR3 more avidly than with HNE, reversing the imbalance in the inflammatory disease state I propose to construct a P7-P3 hypervariable ?1-PI library, using the PCR-based mutagenesis approaches and phage packaging kits that have proven successful in screens for preferential FXIa and thrombin inhibition over HNE. ?1-PI variants will undergo biopanning including a positive selection for PR3 and negative selection for HNE, allowing for determination of PR3 specific inhibitors. The remaining sequences will be expressed as recombinant ?1-PI proteins for kinetic characterization. The new knowledge obtained from this will shed light on selective inhibition of PR3 in inflammatory diseases such as granulomatosis with polyangiitis (GPA).
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367269
Name
Perruzza Darian L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Selective inhibition of proteinase 3 over human neutrophil elastase by alpha1-protease inhibitor
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alpha1-Proteinase Inhibitor; Autoimmune Disorders; Biopanning; Neutrophil; Phage Display; Protein Mutagenesis; Proteinase 3; Reactive Centre Loop; Selective Inhibition; Serine Proteinase Inhibitors
Abstract
Neutrophils, though important components of the immune system, can amplify the damage caused in autoimmune diseases by attacking healthy human tissue in the absence of infection. When activated, neutrophils release reactive oxygen species and neutrophil serine proteases (NSP), including proteinase 3 (PR3). Endogenous NSP inhibitors are overwhelmed in inflammatory disease states, leading to damage. Natural NSP inhibitors preferentially inhibit the NSP human neutrophil elastase (HNE), thus, other NSPs like PR3 offer attractive therapeutic targets. A well-known and abundant HNE inhibitor, ?1-protease inhibitor (?1-PI), has been found to preferentially inhibit thrombin and FXIa when the reactive centre loop is mutated. As of yet, there has been no inhibitor, natural or engineered, that successfully, efficiently and preferentially inhibits PR3 over HNE in vivo. The objective of my M.Sc. thesis research will be to select and characterize recombinant ?1-PI variants that react with PR3 more avidly than with HNE, reversing the imbalance in the inflammatory disease state I propose to construct a P7-P3 hypervariable ?1-PI library, using the PCR-based mutagenesis approaches and phage packaging kits that have proven successful in screens for preferential FXIa and thrombin inhibition over HNE. ?1-PI variants will undergo biopanning including a positive selection for PR3 and negative selection for HNE, allowing for determination of PR3 specific inhibitors. The remaining sequences will be expressed as recombinant ?1-PI proteins for kinetic characterization. The new knowledge obtained from this will shed light on selective inhibition of PR3 in inflammatory diseases such as granulomatosis with polyangiitis (GPA).
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Perruzza, Darian L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~